{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"], "versionId": "7", "lastUpdated": "2025-03-16T11:59:31.863Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/293876", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313880"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85789"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73212"}], "name": "End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313880", "title": "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "InterventionOnlyEvidence", "display": "InterventionOnlyEvidence"}]}}], "variableDefinition": [{"description": "Adults with type 2 diabetes with moderate CV risk -- GLP-1 RA", "variableRole": "population", "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85390-I-85789", "assigner": {"display": "Computable Publishing LLC"}}, "display": "GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk", "reference": "Group/236535"}}, {"description": "End-stage kidney disease", "variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313880", "assigner": {"display": "Computable Publishing LLC"}}, "display": "End-stage kidney disease", "reference": "EvidenceVariable/236551"}}], "statistic": [{"description": "Risk 1.6%", "statisticType": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-type", "version": "5.0.0-cibuild", "code": "C44256", "display": "Proportion"}]}, "quantity": {"value": 0.016}}], "url": "https://fevir.net/resources/Evidence/293876", "id": "293876", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}